Lv1
10 积分 2022-08-25 加入
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
7小时前
已完结
Imlunestrant: First Approval
1个月前
已完结
Comparison of design methods for a safety run-in phase of a phase II clinical trial
6个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
6个月前
已完结
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
7个月前
已完结
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer
7个月前
已完结
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates
8个月前
已完结
皖公网安备34019202002308
